GILEAD SCIENCES, INC.

Gilead Sciences, Inc. (including its consolidated subsidiaries, referred to as Gilead, the company, we, our or us ) is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. We are committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19 and cancer. We operate in more than 35 countries worldwide, with headquarters in Foster City, California. Our Business Products We have transformed care for people around the world by discovering, developing and delivering innovative medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Our innovative medicines represent advancements by offering first-in-class therapies, greater efficacy, enhanced modes of delivery, more convenient treatment and prevention regimens, improved resistance profiles and reduced side effects. In 2025, our commercial portfolio included more than 25 therapies, including the following products and collaboration products with approved indications in the U.S.: HIV Biktarvy is an oral formulation dosed once a day for the treatment of HIV-1 infection in certain patients. Biktarvy is a single-tablet regimen of a fixed-dose combination of our antiretroviral medications, bictegravir, emtricitabine ( FTC ) and tenofovir alafenamide ( TAF ). Descovy is an oral formulation indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in certain patients.